DK3360580T3 - METHOD OF GENETIC TREATMENT USING THE AAV-XBP1S / GFP VIRUSE AND ITS USE IN THE PREVENTION AND TREATMENT OF AMYOTROPHICAL LATERAL SCLEROSIS - Google Patents
METHOD OF GENETIC TREATMENT USING THE AAV-XBP1S / GFP VIRUSE AND ITS USE IN THE PREVENTION AND TREATMENT OF AMYOTROPHICAL LATERAL SCLEROSIS Download PDFInfo
- Publication number
- DK3360580T3 DK3360580T3 DK16852956.8T DK16852956T DK3360580T3 DK 3360580 T3 DK3360580 T3 DK 3360580T3 DK 16852956 T DK16852956 T DK 16852956T DK 3360580 T3 DK3360580 T3 DK 3360580T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- amyotrophical
- xbp1s
- viruse
- aav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2015003024A CL2015003024A1 (en) | 2015-10-09 | 2015-10-09 | Method of genetic treatment using aav-xbp1s / gfp virus, and its use in the prevention and treatment of amyotrophic lateral sclerosis. |
PCT/CL2016/000056 WO2017059554A1 (en) | 2015-10-09 | 2016-09-30 | Method for genetic treatment using the aav-xbp1s/gfp virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3360580T3 true DK3360580T3 (en) | 2022-02-21 |
Family
ID=56081079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16852956.8T DK3360580T3 (en) | 2015-10-09 | 2016-09-30 | METHOD OF GENETIC TREATMENT USING THE AAV-XBP1S / GFP VIRUSE AND ITS USE IN THE PREVENTION AND TREATMENT OF AMYOTROPHICAL LATERAL SCLEROSIS |
Country Status (14)
Country | Link |
---|---|
US (1) | US10512698B2 (en) |
EP (2) | EP3360580B1 (en) |
AU (1) | AU2016336063B2 (en) |
CL (1) | CL2015003024A1 (en) |
CY (1) | CY1125031T1 (en) |
DK (1) | DK3360580T3 (en) |
ES (1) | ES2907684T3 (en) |
HR (1) | HRP20220199T1 (en) |
HU (1) | HUE057861T2 (en) |
LT (1) | LT3360580T (en) |
PL (1) | PL3360580T3 (en) |
PT (1) | PT3360580T (en) |
SI (1) | SI3360580T1 (en) |
WO (1) | WO2017059554A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2015003242A1 (en) * | 2015-11-04 | 2016-10-14 | Univ Chile | Aav / upr-plus virus, upr-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as parkinson's and huntington diseases, among others. |
US20220184175A1 (en) * | 2019-02-01 | 2022-06-16 | Universidad De Chile | Treatment of aging or age-related disorders using xbp1 |
CN112143693A (en) * | 2019-06-28 | 2020-12-29 | 杭州康万达医药科技有限公司 | Method for producing virus and harvesting solution composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2489733T (en) | 2006-06-07 | 2019-05-27 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
LT3146982T (en) | 2006-10-03 | 2019-11-11 | Genzyme Corp | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
US20110142799A1 (en) * | 2008-06-23 | 2011-06-16 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
CL2014003590A1 (en) * | 2014-12-30 | 2015-07-10 | Univ Chile | Aav / xbp1s-ha virus, method of genetic treatment and its use in the optimization and improvement of cognitive, memory and learning abilities. |
-
2015
- 2015-10-09 CL CL2015003024A patent/CL2015003024A1/en unknown
-
2016
- 2016-09-30 SI SI201631478T patent/SI3360580T1/en unknown
- 2016-09-30 HR HRP20220199TT patent/HRP20220199T1/en unknown
- 2016-09-30 ES ES16852956T patent/ES2907684T3/en active Active
- 2016-09-30 EP EP16852956.8A patent/EP3360580B1/en active Active
- 2016-09-30 PT PT168529568T patent/PT3360580T/en unknown
- 2016-09-30 HU HUE16852956A patent/HUE057861T2/en unknown
- 2016-09-30 PL PL16852956T patent/PL3360580T3/en unknown
- 2016-09-30 AU AU2016336063A patent/AU2016336063B2/en active Active
- 2016-09-30 EP EP21209131.8A patent/EP4035687A1/en active Pending
- 2016-09-30 LT LTEPPCT/CL2016/000056T patent/LT3360580T/en unknown
- 2016-09-30 WO PCT/CL2016/000056 patent/WO2017059554A1/en active Application Filing
- 2016-09-30 DK DK16852956.8T patent/DK3360580T3/en active
- 2016-09-30 US US15/767,086 patent/US10512698B2/en active Active
-
2022
- 2022-03-01 CY CY20221100171T patent/CY1125031T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3360580A4 (en) | 2019-03-13 |
HRP20220199T1 (en) | 2022-04-29 |
US10512698B2 (en) | 2019-12-24 |
PT3360580T (en) | 2022-02-24 |
ES2907684T3 (en) | 2022-04-26 |
US20190030188A1 (en) | 2019-01-31 |
AU2016336063A1 (en) | 2018-05-24 |
CY1125031T1 (en) | 2023-03-24 |
EP3360580B1 (en) | 2021-12-01 |
EP4035687A1 (en) | 2022-08-03 |
SI3360580T1 (en) | 2022-05-31 |
AU2016336063B2 (en) | 2023-07-13 |
PL3360580T3 (en) | 2022-05-23 |
EP3360580A1 (en) | 2018-08-15 |
WO2017059554A1 (en) | 2017-04-13 |
LT3360580T (en) | 2022-05-10 |
HUE057861T2 (en) | 2022-06-28 |
CL2015003024A1 (en) | 2016-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3445388T3 (en) | Materials and methods for the treatment of hemoglobinopathies | |
DK3386484T3 (en) | COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS | |
DK3102673T3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA-TALASSEMI | |
DK3259597T3 (en) | PVRIG POLYPEPTIDES AND METHODS OF TREATMENT | |
DK3189655T3 (en) | COMPUTER-IMPLEMENTED PROCEDURE AND SYSTEM FOR REMOVING SUPPORT SUPPORT FOR VISUALLY IMPAIRED USERS | |
DK3149019T3 (en) | Cholan derivatives for use in the treatment and / or prevention of FXR- and TGR5 / GPBAR1-mediated diseases | |
DK3285809T3 (en) | INHIBITORS OF IMMUNCTION POINT MODULATORS FOR USE IN TREATMENT OF CANCER AND INFECTIONS. | |
DK3096798T3 (en) | PLASMA CALLIC BINDING PROTEINS AND USES THEREOF FOR THE TREATMENT OF HEREDITARY ANGIOEDEM | |
DK3119797T3 (en) | RAAV-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | |
DK3426781T3 (en) | MICRO-RNAS AND METHODS OF USING THEREOF | |
DK3350201T3 (en) | Manipulated phytases and methods of using the same | |
DK3394065T3 (en) | TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USING IT | |
DK3481846T3 (en) | 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA-RELATED CONDITIONS | |
DK3307296T3 (en) | TIMP2 FOR USE IN THE TREATMENT OF AGING ASSOCIATED CONDITIONS | |
DK3347014T3 (en) | Methods for diagnosing and treating Tourette's syndrome | |
DK3242947T3 (en) | GENTERAPY AND ELECTROPORESIS FOR THE TREATMENT OF MALIGNITIES | |
DK3303339T3 (en) | PDE9 INHIBITORS WITH THE IMIDAZOTRIAZINON SKELELINE AND IMIDAZOPYRAZINON SKELELINE FOR THE TREATMENT OF PERIOD DISEASES | |
DK3189074T3 (en) | Compositions and methods for the treatment and prevention of inflammation | |
DK3197472T3 (en) | RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURI | |
DK3142664T3 (en) | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSTICATION OF EYE DISEASES | |
DK3110446T3 (en) | Methods and compositions for treating Siglec-8-associated diseases | |
DK3268315T3 (en) | SYSTEM AND METHOD OF TREATING FLUIDS USING SONOELECTROCHEMISTRY | |
DK3310190T3 (en) | Composition for the treatment and use of meat | |
DK3334693T3 (en) | CONTINUOUS PROCEDURE AND SYSTEM FOR THE WASTE TREATMENT | |
DK3107902T3 (en) | CONNECTIONS AND METHODS OF INHIBITING FASCIN |